“On Thursday (Dec. 14), [Nigeria] signed five grant agreements with the Global Fund to Fight AIDS, Tuberculosis and Malaria,” with some of the money going “to provide for antiretroviral therapy treatment and prevention services, particularly on mother-to-child HIV transmission,” Devex’s “The Development Newswire” blog reports. Of the total $335 million, $265 million will go toward HIV/AIDS activities, while $70 million will be used for TB initiatives, the blog notes (Ravelo, 12/14). “For Nigeria, [the] grant agreements address a tremendous need: Nigeria has the second highest number of people living with HIV in the world and only 30 percent of people requiring HIV treatment are receiving antiretroviral therapy,” a Global Fund press release states (12/13).
Noting that the WHO’s Global Tuberculosis Report shows “that access to care and treatment for tuberculosis [TB] has expanded substantially in the past two decades,” Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, writes in an AlertNet opinion piece, “Not only is this good news for those countries that are most vulnerable to tuberculosis; it is also good news for the global community,” as TB can be passed through the air. Derrick describes some of the interventions against TB instituted internationally, and she notes the Global Fund to Fight AIDS, Tuberculosis and Malaria “is the largest global donor to tuberculosis programs, providing 82 percent of international funding to fight the disease,” as well as “91 percent of international financing” to fight multidrug-resistant TB (MDR-TB).
PEPFAR will purchase up to 150 rapid tuberculosis (TB) Xpert testing devices and cartridges to test about 450,000 people for TB, “addressing a need to improve diagnoses of drug-resistant strains of disease, and to identify the disease in HIV-positive people in sub-Saharan Africa and Myanmar, the Office of the Global AIDS Coordinator announced” Tuesday, the Center for Global Health Policy’s “Science Speaks” blog reports. “The investment is part of an ongoing effort,” according to the blog, which notes, “The announcement of the program’s added investment in the Cepheid Xpert tests, following the pre-World AIDS Day release last week of PEPFAR’s blueprint for creating an AIDS-free generation backs the plan’s stated purpose of applying evidence-based approaches and scientific advances to confront the global HIV epidemic” (Barton, 12/4).
In the New York Times’ “Scientist At Work” blog, Alexander Kumar, a physician and researcher at Concordia Station in Antarctica, examines the question of “why humans should venture out to other planets, and perhaps in the process create new problems, when we have so many problems on our own planet,” including HIV, malaria, tuberculosis and other “largely preventable and treatable” conditions. Kumar, who is “investigat[ing] the possibility of one day sending humans to Mars” for the European Space Agency, says he is “repeatedly asked … why the human race would invest its precious and finite resources (money) into space exploration?” He continues, “People have presented valid arguments both ways: those against, about depriving the bottom billion of our planet by diverting much-needed funding; and those in favor, for furthering mankind’s now-desperate need for discoveries and new life-saving technology through exploration in space.
The Financial Times on Friday published a special report titled, “FT Health: Combating AIDS 2012” (.pdf). The report, released ahead of World AIDS Day, observed annually on December 1, includes several pieces, including an article discussing human behavior as an obstacle to eradicating HIV, an article examining Global Fund reform, and an article examining how the number of AIDS-related deaths could be reduced by more effectively treating tuberculosis patients (11/30).
Writing in the Global Health Technologies Coalition’s “Breakthroughs” blog, Eleonora Jimenez-Levi, a senior researcher at the Treatment Action Group (TAG), examines the 2012 Report on Tuberculosis Research Funding Trends: 2005â€“2011,”the latest report on the state of funding for tuberculosis (TB) research and product development.” Jimenez-Levi recaps the findings and recommendations of the report and concludes, “Promising new tools are on the horizon, but without political will and adequate funding to support the development of new vaccines, diagnostics, and drugs, the world will not be able to contain the growing problem that drug-resistant TB poses, much less eliminate TB as a public health threat by 2050” (11/27).
UNAIDS and the Stop TB Partnership on Tuesday launched an “initiative aimed at reducing HIV deaths caused by tuberculosis (TB) by half” by 2015, the U.N. News Centre reports (11/27). The memorandum of understanding signed by the groups states they will “take action … to strategically address the intolerable burden of TB mortality borne by people living with HIV,” according to a UNAIDS press release. “The two organizations are developing a detailed work plan and have committed to collaboration to achieve three main objectives within the next three years: increase political commitment and resource mobilization for TB/HIV; strengthen knowledge, capacity and engagement of civil society organizations, affected communities and the private sector; and help most-affected countries integrate TB/HIV services,” the press release continues (11/27). “TB/HIV is a deadly combination. We can stop people from dying of HIV/TB co-infection through integration and simplification of HIV and TB services,” UNAIDS Executive Director Michel Sidibe said, according to the U.N. News Centre (11/27).
“More than one-quarter of people diagnosed with tuberculosis [TB] at a clinic in India’s largest city of 18 million have a strain that doesn’t respond to the main treatment against the disease, according to preliminary data from a new diagnostic being tested,” the Wall Street Journal reports. The newspaper obtained “preliminary and not peer reviewed” data from TB clinics in Mumbai, and Puneet Dewan with the Bill & Melinda Gates Foundation TB program in India “said the WHO and Indian authorities are taking the data seriously because it appears to confirm other studies in recent years of similarly high rates of multi-drug-resistance, in which patients don’t respond to the two most powerful TB medicines.” According to the newspaper, “The WHO and India currently estimate India has about 100,000 of the 650,000 people in the world with multi-drug-resistance” (Anand/McKay, 11/23).
UNAIDS’ new World AIDS Day report: Results, released on Tuesday, “shows that unprecedented acceleration in the AIDS response is producing results for people,” according to a UNAIDS press release. Between 2001 and 2011, “a more than 50 percent reduction in the rate of new HIV infections has been achieved across 25 low- and middle-income countries — more than half in Africa, the region most affected by HIV,” the press release states, adding, “In addition to welcome results in HIV prevention, sub-Saharan Africa has reduced AIDS-related deaths by one third in the last six years and increased the number of people on antiretroviral treatment by 59 percent in the last two years alone.” According to the press release, “The area where perhaps most progress is being made is in reducing new HIV infections in children,” and the number of AIDS-related deaths has dropped because of increased access to antiretroviral treatment.
According to a new report (.pdf) released by Medecins Sans Frontieres (MSF) at the Union World Conference on Lung Health in Kuala Lumpur, many tuberculosis (TB) programs “under-diagnose, under-treat or completely leave children with TB out, despite the increase in pediatric TB, and rising numbers of children who are infected with drug-resistant forms of TB strains,” PlusNews reports. The report, based on “data collected over three years from over 2,000 children with TB in 13 MSF projects across six countries,” found that diagnosis of children using the most commonly used TB test is inaccurate and pediatric TB drug formulations and treatment guidelines are inadequate, the news service notes. MSF called for the development of new TB tests that do not require sputum samples or laboratory infrastructure and “urged WHO to provide clear guidance to drug manufacturers on needed fixed-dose combinations of first-line drugs to support implementation of the new WHO-recommended dosages,” PlusNews writes (11/16).